Sentynl Therapeutics secures $40 million deal with Mereo Biopharma for exclusive marketing rights of alvelestat in the U.S. The agreement includes upfront and R&D payments.

Sentynl Therapeutics has paid an undisclosed fee for the exclusive option to market Mereo Biopharma’s drug alvelestat in the U.S. If Sentynl exercises that option, it will pay $40 million to Mereo. This payment covers the deal’s upfront and R&D expenses until the submission of a new drug application. This strategic move highlights Sentynl's growth plans and commitment to advancing valuable treatments.